nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—urinary bladder cancer	0.519	1	CbGaD
Dapagliflozin—UGT2B7—Epirubicin—urinary bladder cancer	0.0595	0.255	CbGbCtD
Dapagliflozin—ABCB1—Mitomycin—urinary bladder cancer	0.0387	0.166	CbGbCtD
Dapagliflozin—CYP2A6—Fluorouracil—urinary bladder cancer	0.0285	0.122	CbGbCtD
Dapagliflozin—CYP3A4—Thiotepa—urinary bladder cancer	0.0176	0.0753	CbGbCtD
Dapagliflozin—SLC5A4—urine—urinary bladder cancer	0.0156	0.241	CbGeAlD
Dapagliflozin—SLC5A2—urine—urinary bladder cancer	0.0118	0.183	CbGeAlD
Dapagliflozin—ABCB1—Gemcitabine—urinary bladder cancer	0.0111	0.0477	CbGbCtD
Dapagliflozin—CYP1A2—Fluorouracil—urinary bladder cancer	0.0109	0.0467	CbGbCtD
Dapagliflozin—CYP2C9—Fluorouracil—urinary bladder cancer	0.00981	0.042	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—urinary bladder cancer	0.00909	0.0389	CbGbCtD
Dapagliflozin—CYP2C9—Cisplatin—urinary bladder cancer	0.00834	0.0357	CbGbCtD
Dapagliflozin—ABCB1—Cisplatin—urinary bladder cancer	0.00809	0.0347	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—urinary bladder cancer	0.00795	0.0341	CbGbCtD
Dapagliflozin—ABCB1—Doxorubicin—urinary bladder cancer	0.00542	0.0232	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—urinary bladder cancer	0.00525	0.0225	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—urinary bladder cancer	0.00511	0.0219	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—urinary bladder cancer	0.00476	0.0204	CbGbCtD
Dapagliflozin—SLC5A4—renal system—urinary bladder cancer	0.00381	0.059	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—urinary bladder cancer	0.00325	0.0139	CbGbCtD
Dapagliflozin—SLC5A1—prostate gland—urinary bladder cancer	0.00321	0.0497	CbGeAlD
Dapagliflozin—SLC5A2—renal system—urinary bladder cancer	0.00289	0.0447	CbGeAlD
Dapagliflozin—SLC5A1—epithelium—urinary bladder cancer	0.00236	0.0365	CbGeAlD
Dapagliflozin—SLC5A1—renal system—urinary bladder cancer	0.00219	0.0339	CbGeAlD
Dapagliflozin—SLC5A2—vagina—urinary bladder cancer	0.00209	0.0324	CbGeAlD
Dapagliflozin—CYP1A2—urine—urinary bladder cancer	0.00171	0.0264	CbGeAlD
Dapagliflozin—UGT2B7—prostate gland—urinary bladder cancer	0.00163	0.0252	CbGeAlD
Dapagliflozin—CYP2C9—urine—urinary bladder cancer	0.00162	0.0251	CbGeAlD
Dapagliflozin—SLC5A1—vagina—urinary bladder cancer	0.00159	0.0245	CbGeAlD
Dapagliflozin—UGT1A9—renal system—urinary bladder cancer	0.00138	0.0213	CbGeAlD
Dapagliflozin—CYP3A4—urine—urinary bladder cancer	0.00124	0.0191	CbGeAlD
Dapagliflozin—CYP2D6—urine—urinary bladder cancer	0.00122	0.0188	CbGeAlD
Dapagliflozin—CYP2A6—prostate gland—urinary bladder cancer	0.00117	0.0181	CbGeAlD
Dapagliflozin—UGT2B7—renal system—urinary bladder cancer	0.00111	0.0172	CbGeAlD
Dapagliflozin—CYP2A6—seminal vesicle—urinary bladder cancer	0.000988	0.0153	CbGeAlD
Dapagliflozin—UGT2B7—female reproductive system—urinary bladder cancer	0.00089	0.0138	CbGeAlD
Dapagliflozin—CYP2A6—vagina—urinary bladder cancer	0.000577	0.00892	CbGeAlD
Dapagliflozin—CYP1A1—epithelium—urinary bladder cancer	0.000445	0.00688	CbGeAlD
Dapagliflozin—CYP1A2—renal system—urinary bladder cancer	0.000418	0.00647	CbGeAlD
Dapagliflozin—CYP1A1—renal system—urinary bladder cancer	0.000413	0.00638	CbGeAlD
Dapagliflozin—CYP1A1—urethra—urinary bladder cancer	0.000405	0.00627	CbGeAlD
Dapagliflozin—CYP1A1—female reproductive system—urinary bladder cancer	0.00033	0.00511	CbGeAlD
Dapagliflozin—CYP2C9—female reproductive system—urinary bladder cancer	0.000318	0.00492	CbGeAlD
Dapagliflozin—ABCB1—prostate gland—urinary bladder cancer	0.000314	0.00486	CbGeAlD
Dapagliflozin—CYP3A4—renal system—urinary bladder cancer	0.000303	0.00468	CbGeAlD
Dapagliflozin—CYP1A1—vagina—urinary bladder cancer	0.000299	0.00462	CbGeAlD
Dapagliflozin—CYP2D6—renal system—urinary bladder cancer	0.000298	0.00461	CbGeAlD
Dapagliflozin—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.000292	0.00348	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.00029	0.00345	CcSEcCtD
Dapagliflozin—Dehydration—Cisplatin—urinary bladder cancer	0.000288	0.00343	CcSEcCtD
Dapagliflozin—Influenza—Gemcitabine—urinary bladder cancer	0.000287	0.00342	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—urinary bladder cancer	0.000287	0.00341	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—urinary bladder cancer	0.000284	0.00338	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Cisplatin—urinary bladder cancer	0.000283	0.00337	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.000277	0.00329	CcSEcCtD
Dapagliflozin—Angina pectoris—Fluorouracil—urinary bladder cancer	0.000275	0.00327	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.00027	0.00321	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.000269	0.00319	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—urinary bladder cancer	0.000269	0.00319	CcSEcCtD
Dapagliflozin—Urethral disorder—Thiotepa—urinary bladder cancer	0.000268	0.00319	CcSEcCtD
Dapagliflozin—ABCB1—seminal vesicle—urinary bladder cancer	0.000266	0.00411	CbGeAlD
Dapagliflozin—Fungal infection—Doxorubicin—urinary bladder cancer	0.000263	0.00312	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.000257	0.00305	CcSEcCtD
Dapagliflozin—Dizziness—Mitomycin—urinary bladder cancer	0.000256	0.00304	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000253	0.003	CcSEcCtD
Dapagliflozin—Infestation—Fluorouracil—urinary bladder cancer	0.000252	0.003	CcSEcCtD
Dapagliflozin—Infestation NOS—Fluorouracil—urinary bladder cancer	0.000252	0.003	CcSEcCtD
Dapagliflozin—Renal failure—Gemcitabine—urinary bladder cancer	0.000252	0.00299	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—urinary bladder cancer	0.000251	0.00299	CcSEcCtD
Dapagliflozin—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.000251	0.00299	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000248	0.00295	CcSEcCtD
Dapagliflozin—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.000247	0.00294	CcSEcCtD
Dapagliflozin—Urinary tract infection—Fluorouracil—urinary bladder cancer	0.000245	0.00291	CcSEcCtD
Dapagliflozin—Rash—Mitomycin—urinary bladder cancer	0.000244	0.0029	CcSEcCtD
Dapagliflozin—Dermatitis—Mitomycin—urinary bladder cancer	0.000243	0.00289	CcSEcCtD
Dapagliflozin—CYP3A4—female reproductive system—urinary bladder cancer	0.000242	0.00375	CbGeAlD
Dapagliflozin—Headache—Mitomycin—urinary bladder cancer	0.000242	0.00288	CcSEcCtD
Dapagliflozin—CYP2D6—female reproductive system—urinary bladder cancer	0.000239	0.00369	CbGeAlD
Dapagliflozin—Malnutrition—Thiotepa—urinary bladder cancer	0.000238	0.00283	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.000238	0.00282	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—urinary bladder cancer	0.000236	0.00281	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000236	0.0028	CcSEcCtD
Dapagliflozin—Renal failure—Cisplatin—urinary bladder cancer	0.000235	0.00279	CcSEcCtD
Dapagliflozin—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000234	0.00278	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—urinary bladder cancer	0.000233	0.00276	CcSEcCtD
Dapagliflozin—ABCB1—epithelium—urinary bladder cancer	0.000231	0.00357	CbGeAlD
Dapagliflozin—Back pain—Thiotepa—urinary bladder cancer	0.00023	0.00274	CcSEcCtD
Dapagliflozin—Nausea—Mitomycin—urinary bladder cancer	0.00023	0.00273	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000227	0.0027	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000226	0.00269	CcSEcCtD
Dapagliflozin—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000226	0.00268	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—urinary bladder cancer	0.000221	0.00263	CcSEcCtD
Dapagliflozin—Infestation—Etoposide—urinary bladder cancer	0.000219	0.0026	CcSEcCtD
Dapagliflozin—Infestation NOS—Etoposide—urinary bladder cancer	0.000219	0.0026	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—urinary bladder cancer	0.000219	0.0026	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000216	0.00256	CcSEcCtD
Dapagliflozin—Renal failure—Etoposide—urinary bladder cancer	0.000215	0.00256	CcSEcCtD
Dapagliflozin—Myocardial infarction—Etoposide—urinary bladder cancer	0.000215	0.00255	CcSEcCtD
Dapagliflozin—ABCB1—renal system—urinary bladder cancer	0.000214	0.00332	CbGeAlD
Dapagliflozin—Neoplasm—Methotrexate—urinary bladder cancer	0.000212	0.00252	CcSEcCtD
Dapagliflozin—Urine output increased—Methotrexate—urinary bladder cancer	0.000212	0.00252	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000212	0.00252	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000211	0.0025	CcSEcCtD
Dapagliflozin—ABCB1—urethra—urinary bladder cancer	0.000211	0.00326	CbGeAlD
Dapagliflozin—Urethral disorder—Cisplatin—urinary bladder cancer	0.00021	0.0025	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—urinary bladder cancer	0.000207	0.00246	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—urinary bladder cancer	0.000207	0.00246	CcSEcCtD
Dapagliflozin—Hypertension—Thiotepa—urinary bladder cancer	0.000206	0.00244	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000201	0.00239	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—urinary bladder cancer	0.000198	0.00236	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000196	0.00232	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000194	0.00231	CcSEcCtD
Dapagliflozin—Back pain—Gemcitabine—urinary bladder cancer	0.000194	0.0023	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—urinary bladder cancer	0.000194	0.0023	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—urinary bladder cancer	0.000193	0.00299	CbGeAlD
Dapagliflozin—Infection—Thiotepa—urinary bladder cancer	0.000193	0.00229	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—urinary bladder cancer	0.000193	0.00229	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—urinary bladder cancer	0.000192	0.00228	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—urinary bladder cancer	0.000192	0.00228	CcSEcCtD
Dapagliflozin—Skin disorder—Thiotepa—urinary bladder cancer	0.000189	0.00224	CcSEcCtD
Dapagliflozin—Malnutrition—Cisplatin—urinary bladder cancer	0.000187	0.00222	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—urinary bladder cancer	0.000185	0.0022	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—urinary bladder cancer	0.000183	0.00218	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000183	0.00218	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000174	0.00206	CcSEcCtD
Dapagliflozin—Hypertension—Gemcitabine—urinary bladder cancer	0.000173	0.00206	CcSEcCtD
Dapagliflozin—ABCB1—female reproductive system—urinary bladder cancer	0.000172	0.00266	CbGeAlD
Dapagliflozin—Phlebitis—Doxorubicin—urinary bladder cancer	0.000171	0.00203	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000169	0.00201	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000169	0.00201	CcSEcCtD
Dapagliflozin—Discomfort—Gemcitabine—urinary bladder cancer	0.000168	0.002	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000168	0.00199	CcSEcCtD
Dapagliflozin—Constipation—Thiotepa—urinary bladder cancer	0.000166	0.00198	CcSEcCtD
Dapagliflozin—Discomfort—Fluorouracil—urinary bladder cancer	0.000166	0.00197	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—urinary bladder cancer	0.000165	0.00197	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000163	0.00194	CcSEcCtD
Dapagliflozin—Oedema—Gemcitabine—urinary bladder cancer	0.000163	0.00194	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000163	0.00194	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000162	0.00193	CcSEcCtD
Dapagliflozin—Infection—Gemcitabine—urinary bladder cancer	0.000162	0.00193	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000161	0.00191	CcSEcCtD
Dapagliflozin—Oedema—Fluorouracil—urinary bladder cancer	0.000161	0.00191	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00016	0.0019	CcSEcCtD
Dapagliflozin—Infection—Fluorouracil—urinary bladder cancer	0.00016	0.0019	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—urinary bladder cancer	0.000159	0.00189	CcSEcCtD
Dapagliflozin—Skin disorder—Gemcitabine—urinary bladder cancer	0.000159	0.00189	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000158	0.00188	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000158	0.00188	CcSEcCtD
Dapagliflozin—Discomfort—Cisplatin—urinary bladder cancer	0.000157	0.00187	CcSEcCtD
Dapagliflozin—ABCB1—vagina—urinary bladder cancer	0.000155	0.0024	CbGeAlD
Dapagliflozin—Urticaria—Thiotepa—urinary bladder cancer	0.000154	0.00183	CcSEcCtD
Dapagliflozin—Body temperature increased—Thiotepa—urinary bladder cancer	0.000154	0.00183	CcSEcCtD
Dapagliflozin—Hypotension—Gemcitabine—urinary bladder cancer	0.000153	0.00182	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000152	0.00181	CcSEcCtD
Dapagliflozin—Oedema—Cisplatin—urinary bladder cancer	0.000152	0.00181	CcSEcCtD
Dapagliflozin—Infection—Cisplatin—urinary bladder cancer	0.000151	0.0018	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000151	0.00179	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.00015	0.00179	CcSEcCtD
Dapagliflozin—Hypotension—Fluorouracil—urinary bladder cancer	0.00015	0.00179	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000149	0.00177	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—urinary bladder cancer	0.000148	0.00176	CcSEcCtD
Dapagliflozin—Skin disorder—Cisplatin—urinary bladder cancer	0.000148	0.00176	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000148	0.00176	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—urinary bladder cancer	0.000148	0.00176	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000147	0.00175	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000147	0.00175	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000145	0.00173	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000145	0.00172	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—urinary bladder cancer	0.000144	0.00171	CcSEcCtD
Dapagliflozin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000143	0.0017	CcSEcCtD
Dapagliflozin—Hypotension—Cisplatin—urinary bladder cancer	0.000142	0.00169	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000142	0.00169	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000141	0.00168	CcSEcCtD
Dapagliflozin—Constipation—Gemcitabine—urinary bladder cancer	0.00014	0.00166	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00014	0.00166	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000139	0.00165	CcSEcCtD
Dapagliflozin—Infection—Etoposide—urinary bladder cancer	0.000139	0.00165	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000138	0.00164	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—urinary bladder cancer	0.000138	0.00164	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—urinary bladder cancer	0.000137	0.00163	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—urinary bladder cancer	0.000137	0.00163	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—urinary bladder cancer	0.000136	0.00161	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000135	0.0016	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000135	0.0016	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—urinary bladder cancer	0.000134	0.00159	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000132	0.00157	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000132	0.00156	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—urinary bladder cancer	0.000131	0.00156	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—urinary bladder cancer	0.000131	0.00156	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—urinary bladder cancer	0.00013	0.00155	CcSEcCtD
Dapagliflozin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000129	0.00154	CcSEcCtD
Dapagliflozin—Renal failure—Methotrexate—urinary bladder cancer	0.000129	0.00153	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—urinary bladder cancer	0.000129	0.00153	CcSEcCtD
Dapagliflozin—Dizziness—Thiotepa—urinary bladder cancer	0.000129	0.00153	CcSEcCtD
Dapagliflozin—Urticaria—Fluorouracil—urinary bladder cancer	0.000128	0.00152	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—urinary bladder cancer	0.000127	0.00151	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—urinary bladder cancer	0.000127	0.00151	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000127	0.00151	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000124	0.00147	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—urinary bladder cancer	0.000123	0.00146	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—urinary bladder cancer	0.000123	0.00146	CcSEcCtD
Dapagliflozin—Rash—Thiotepa—urinary bladder cancer	0.000123	0.00146	CcSEcCtD
Dapagliflozin—Dermatitis—Thiotepa—urinary bladder cancer	0.000122	0.00145	CcSEcCtD
Dapagliflozin—Headache—Thiotepa—urinary bladder cancer	0.000122	0.00145	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—urinary bladder cancer	0.000121	0.00143	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000121	0.00143	CcSEcCtD
Dapagliflozin—Body temperature increased—Cisplatin—urinary bladder cancer	0.00012	0.00143	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—urinary bladder cancer	0.000119	0.00142	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000119	0.00142	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—urinary bladder cancer	0.000119	0.00142	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000118	0.00141	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000118	0.0014	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000116	0.00138	CcSEcCtD
Dapagliflozin—Nausea—Thiotepa—urinary bladder cancer	0.000115	0.00137	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—urinary bladder cancer	0.000115	0.00137	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000114	0.00135	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—urinary bladder cancer	0.000114	0.00135	CcSEcCtD
Dapagliflozin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000112	0.00133	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—urinary bladder cancer	0.000112	0.00133	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—urinary bladder cancer	0.000111	0.00132	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—urinary bladder cancer	0.00011	0.00131	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.00011	0.00131	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000109	0.00129	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000108	0.00129	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—urinary bladder cancer	0.000108	0.00128	CcSEcCtD
Dapagliflozin—Dizziness—Fluorouracil—urinary bladder cancer	0.000106	0.00126	CcSEcCtD
Dapagliflozin—Rash—Gemcitabine—urinary bladder cancer	0.000103	0.00123	CcSEcCtD
Dapagliflozin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000103	0.00122	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000103	0.00122	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—urinary bladder cancer	0.000102	0.00122	CcSEcCtD
Dapagliflozin—Headache—Gemcitabine—urinary bladder cancer	0.000102	0.00122	CcSEcCtD
Dapagliflozin—Rash—Fluorouracil—urinary bladder cancer	0.000101	0.0012	CcSEcCtD
Dapagliflozin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000101	0.0012	CcSEcCtD
Dapagliflozin—Headache—Fluorouracil—urinary bladder cancer	0.000101	0.0012	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000101	0.0012	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—urinary bladder cancer	0.0001	0.00155	CbGeAlD
Dapagliflozin—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.0001	0.00119	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—urinary bladder cancer	9.99e-05	0.00119	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—urinary bladder cancer	9.91e-05	0.00118	CcSEcCtD
Dapagliflozin—Nausea—Gemcitabine—urinary bladder cancer	9.71e-05	0.00115	CcSEcCtD
Dapagliflozin—Rash—Cisplatin—urinary bladder cancer	9.61e-05	0.00114	CcSEcCtD
Dapagliflozin—Dermatitis—Cisplatin—urinary bladder cancer	9.6e-05	0.00114	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—urinary bladder cancer	9.59e-05	0.00114	CcSEcCtD
Dapagliflozin—Nausea—Fluorouracil—urinary bladder cancer	9.55e-05	0.00113	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—urinary bladder cancer	9.27e-05	0.0011	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—urinary bladder cancer	9.23e-05	0.0011	CcSEcCtD
Dapagliflozin—Nausea—Cisplatin—urinary bladder cancer	9.05e-05	0.00108	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—urinary bladder cancer	8.87e-05	0.00105	CcSEcCtD
Dapagliflozin—Rash—Etoposide—urinary bladder cancer	8.8e-05	0.00105	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—urinary bladder cancer	8.79e-05	0.00105	CcSEcCtD
Dapagliflozin—Headache—Etoposide—urinary bladder cancer	8.74e-05	0.00104	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.66e-05	0.00103	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—urinary bladder cancer	8.62e-05	0.00102	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—urinary bladder cancer	8.58e-05	0.00102	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—urinary bladder cancer	8.36e-05	0.000994	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—urinary bladder cancer	8.31e-05	0.000987	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—urinary bladder cancer	8.29e-05	0.000986	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—urinary bladder cancer	8.28e-05	0.000984	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—urinary bladder cancer	8.12e-05	0.000965	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.11e-05	0.000963	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—urinary bladder cancer	8.08e-05	0.000961	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—urinary bladder cancer	8.06e-05	0.000959	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—urinary bladder cancer	7.82e-05	0.00093	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.82e-05	0.00093	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—urinary bladder cancer	7.81e-05	0.000929	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—urinary bladder cancer	7.77e-05	0.000924	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—urinary bladder cancer	7.66e-05	0.00091	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—urinary bladder cancer	7.6e-05	0.000903	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—urinary bladder cancer	7.56e-05	0.000899	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.5e-05	0.000891	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—urinary bladder cancer	7.46e-05	0.000887	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—urinary bladder cancer	7.31e-05	0.000869	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—urinary bladder cancer	7.24e-05	0.000861	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	7.24e-05	0.000861	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.22e-05	0.000858	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—urinary bladder cancer	7.19e-05	0.000855	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—urinary bladder cancer	7.03e-05	0.000836	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	7e-05	0.000832	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—urinary bladder cancer	6.77e-05	0.000804	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.76e-05	0.000803	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—urinary bladder cancer	6.69e-05	0.000795	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—urinary bladder cancer	6.64e-05	0.000789	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—urinary bladder cancer	6.61e-05	0.000786	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.25e-05	0.000743	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—urinary bladder cancer	6.22e-05	0.000739	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—urinary bladder cancer	6.19e-05	0.000736	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—urinary bladder cancer	6.19e-05	0.000735	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—urinary bladder cancer	6.16e-05	0.000732	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—urinary bladder cancer	5.76e-05	0.000685	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—urinary bladder cancer	5.75e-05	0.000684	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—urinary bladder cancer	5.72e-05	0.00068	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—urinary bladder cancer	5.53e-05	0.000657	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.33e-05	0.000634	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—urinary bladder cancer	5.27e-05	0.000627	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—urinary bladder cancer	5.27e-05	0.000626	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—urinary bladder cancer	5.24e-05	0.000623	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—urinary bladder cancer	5.17e-05	0.000615	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—urinary bladder cancer	4.97e-05	0.00059	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—urinary bladder cancer	4.93e-05	0.000586	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—urinary bladder cancer	4.93e-05	0.000586	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—urinary bladder cancer	4.9e-05	0.000583	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—urinary bladder cancer	4.79e-05	0.000569	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—urinary bladder cancer	4.65e-05	0.000552	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—urinary bladder cancer	4.56e-05	0.000543	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—urinary bladder cancer	4.56e-05	0.000542	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—urinary bladder cancer	4.54e-05	0.000539	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—urinary bladder cancer	4.3e-05	0.000511	CcSEcCtD
Dapagliflozin—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	1.56e-05	0.000158	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—urinary bladder cancer	1.56e-05	0.000158	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—urinary bladder cancer	1.56e-05	0.000158	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.55e-05	0.000156	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC19A1—urinary bladder cancer	1.55e-05	0.000156	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—EP300—urinary bladder cancer	1.54e-05	0.000155	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—EP300—urinary bladder cancer	1.54e-05	0.000155	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.53e-05	0.000154	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	1.52e-05	0.000153	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ENO2—urinary bladder cancer	1.52e-05	0.000153	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.51e-05	0.000152	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PRSS3—urinary bladder cancer	1.51e-05	0.000152	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.000151	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	1.5e-05	0.000151	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NAT1—urinary bladder cancer	1.5e-05	0.000151	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NAT1—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—urinary bladder cancer	1.48e-05	0.000149	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	1.47e-05	0.000148	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NAT2—urinary bladder cancer	1.46e-05	0.000147	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.46e-05	0.000147	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.45e-05	0.000146	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.45e-05	0.000146	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTGS2—urinary bladder cancer	1.43e-05	0.000144	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	1.42e-05	0.000143	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.37e-05	0.000138	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	1.36e-05	0.000137	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.35e-05	0.000136	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	1.34e-05	0.000135	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.33e-05	0.000134	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.31e-05	0.000132	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.3e-05	0.000131	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	1.27e-05	0.000128	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NAT1—urinary bladder cancer	1.27e-05	0.000128	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RRM2—urinary bladder cancer	1.26e-05	0.000127	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—urinary bladder cancer	1.26e-05	0.000126	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—urinary bladder cancer	1.26e-05	0.000126	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.000126	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.25e-05	0.000126	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—urinary bladder cancer	1.24e-05	0.000125	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.23e-05	0.000124	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.23e-05	0.000124	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.22e-05	0.000123	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	1.22e-05	0.000123	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.21e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMP—urinary bladder cancer	1.2e-05	0.000121	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.2e-05	0.000121	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—EP300—urinary bladder cancer	1.19e-05	0.00012	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.19e-05	0.000119	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.18e-05	0.000119	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ENO2—urinary bladder cancer	1.17e-05	0.000118	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	1.17e-05	0.000118	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TYMS—urinary bladder cancer	1.17e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.16e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	1.16e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.16e-05	0.000117	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	1.15e-05	0.000116	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000116	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000116	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.14e-05	0.000115	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.14e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.13e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	1.13e-05	0.000114	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	1.12e-05	0.000113	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.000111	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NAT2—urinary bladder cancer	1.09e-05	0.00011	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	0.000109	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.08e-05	0.000109	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.05e-05	0.000106	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	1.04e-05	0.000105	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.03e-05	0.000104	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.03e-05	0.000104	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.02e-05	0.000103	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	0.000103	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.86e-06	9.93e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	9.85e-06	9.93e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAT1—urinary bladder cancer	9.78e-06	9.85e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	9.78e-06	9.85e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMP—urinary bladder cancer	9.62e-06	9.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	9.6e-06	9.68e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TYMS—urinary bladder cancer	9.47e-06	9.54e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	9.44e-06	9.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NQO1—urinary bladder cancer	9.42e-06	9.49e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RRM2—urinary bladder cancer	9.4e-06	9.47e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	9.36e-06	9.43e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	9.36e-06	9.43e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	9.23e-06	9.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMP—urinary bladder cancer	9.06e-06	9.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	9.01e-06	9.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMP—urinary bladder cancer	8.98e-06	9.05e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—GPX1—urinary bladder cancer	8.97e-06	9.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	8.94e-06	9.01e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	8.8e-06	8.87e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	8.79e-06	8.86e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	8.72e-06	8.79e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ENO2—urinary bladder cancer	8.71e-06	8.77e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HPGDS—urinary bladder cancer	8.71e-06	8.77e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NAT2—urinary bladder cancer	8.7e-06	8.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	8.65e-06	8.72e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.63e-06	8.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTT1—urinary bladder cancer	8.44e-06	8.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	8.31e-06	8.38e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	8.28e-06	8.34e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—urinary bladder cancer	8.26e-06	8.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NAT2—urinary bladder cancer	8.2e-06	8.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NAT2—urinary bladder cancer	8.12e-06	8.19e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.05e-06	8.11e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CREBBP—urinary bladder cancer	7.93e-06	7.99e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	7.85e-06	7.91e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	7.75e-06	7.81e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.7e-06	7.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMP—urinary bladder cancer	7.68e-06	7.73e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	7.61e-06	7.66e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RRM2—urinary bladder cancer	7.51e-06	7.56e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.41e-06	7.47e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.37e-06	7.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TYMS—urinary bladder cancer	7.3e-06	7.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	7.22e-06	7.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	7.22e-06	7.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RRM2—urinary bladder cancer	7.07e-06	7.13e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NQO1—urinary bladder cancer	7.02e-06	7.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RRM2—urinary bladder cancer	7.01e-06	7.07e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HPGDS—urinary bladder cancer	6.95e-06	7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ENO2—urinary bladder cancer	6.95e-06	7e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NAT2—urinary bladder cancer	6.94e-06	7e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—GPX1—urinary bladder cancer	6.91e-06	6.96e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	6.81e-06	6.86e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	6.79e-06	6.84e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTT1—urinary bladder cancer	6.74e-06	6.79e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—urinary bladder cancer	6.71e-06	6.76e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	6.55e-06	6.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ENO2—urinary bladder cancer	6.55e-06	6.6e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	6.5e-06	6.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ENO2—urinary bladder cancer	6.5e-06	6.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	6.5e-06	6.54e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.46e-06	6.51e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	6.45e-06	6.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	6.38e-06	6.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	6.35e-06	6.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.31e-06	6.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	6.3e-06	6.35e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.2e-06	6.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.99e-06	6.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.94e-06	5.98e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMP—urinary bladder cancer	5.93e-06	5.97e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	5.85e-06	5.9e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—urinary bladder cancer	5.67e-06	5.71e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.66e-06	5.7e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NQO1—urinary bladder cancer	5.6e-06	5.65e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	5.55e-06	5.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ENO2—urinary bladder cancer	5.55e-06	5.59e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.52e-06	5.56e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—urinary bladder cancer	5.44e-06	5.48e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—urinary bladder cancer	5.4e-06	5.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.38e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	5.38e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	5.38e-06	5.42e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.36e-06	5.4e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.3e-06	5.34e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NQO1—urinary bladder cancer	5.28e-06	5.32e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	5.28e-06	5.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NQO1—urinary bladder cancer	5.24e-06	5.27e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—urinary bladder cancer	5.17e-06	5.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GPX1—urinary bladder cancer	5.15e-06	5.19e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.08e-06	5.12e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	5.06e-06	5.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	4.97e-06	5.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	4.75e-06	4.79e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.67e-06	4.71e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.63e-06	4.66e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—urinary bladder cancer	4.6e-06	4.64e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.47e-06	4.51e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.43e-06	4.46e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	4.4e-06	4.44e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—urinary bladder cancer	4.39e-06	4.42e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	4.37e-06	4.4e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.35e-06	4.38e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.34e-06	4.37e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.3e-06	4.33e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.3e-06	4.33e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.28e-06	4.32e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.28e-06	4.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.22e-06	4.26e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.15e-06	4.19e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.11e-06	4.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—urinary bladder cancer	4.1e-06	4.13e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	4.07e-06	4.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.06e-06	4.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	4.05e-06	4.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	4.05e-06	4.08e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.04e-06	4.07e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.01e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.01e-06	4.04e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GPX1—urinary bladder cancer	3.88e-06	3.91e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—urinary bladder cancer	3.85e-06	3.88e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GPX1—urinary bladder cancer	3.84e-06	3.87e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	3.81e-06	3.83e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.8e-06	3.82e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.79e-06	3.81e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	3.77e-06	3.8e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.73e-06	3.76e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	3.7e-06	3.73e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.61e-06	3.64e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	3.58e-06	3.6e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—urinary bladder cancer	3.55e-06	3.58e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	3.55e-06	3.57e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.47e-06	3.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.45e-06	3.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.43e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.43e-06	3.45e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—urinary bladder cancer	3.38e-06	3.41e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.28e-06	3.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.22e-06	3.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.08e-06	3.1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	3.03e-06	3.05e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.03e-06	3.05e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.96e-06	2.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.9e-06	2.92e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.88e-06	2.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—urinary bladder cancer	2.88e-06	2.9e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.79e-06	2.81e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	2.76e-06	2.78e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.68e-06	2.7e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.65e-06	2.67e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.65e-06	2.67e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.64e-06	2.66e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.53e-06	2.55e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.52e-06	2.54e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.49e-06	2.51e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.46e-06	2.48e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.42e-06	2.44e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.36e-06	2.38e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.34e-06	2.36e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	2.28e-06	2.3e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.26e-06	2.28e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.11e-06	2.13e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—urinary bladder cancer	2.01e-06	2.03e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.99e-06	2.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.97e-06	1.99e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.93e-06	1.95e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.9e-06	1.91e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.9e-06	1.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.88e-06	1.9e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.82e-06	1.84e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.69e-06	1.7e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.61e-06	1.62e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.49e-06	1.5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.3e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.24e-06	1.25e-05	CbGpPWpGaD
